<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780869</url>
  </required_header>
  <id_info>
    <org_study_id>ETC 2015-002</org_study_id>
    <nct_id>NCT02780869</nct_id>
  </id_info>
  <brief_title>HEMOBLAST Pivotal Clinical Investigation</brief_title>
  <official_title>Prospective, Randomized, Controlled, Multicenter, Pivotal, Clinical Investigation Evaluating the Safety and Efficacy of HEMOBLAST Bellows in Cardiothoracic, Abdominal, and Orthopedic Lower Extremity Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biom'Up SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biom'Up SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, randomized, controlled study is to evaluate the safety and
      efficacy of a new hemostatic device (HEMOBLAST™ Bellows) compared to a control device,
      absorbable gelatin sponge USP with thrombin.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 18, 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Actual">February 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint of this clinical investigation is non-inferiority of HEMOBLAST™ relative to G+T for success at achieving hemostasis within 6 minutes.</measure>
    <time_frame>Intraoperative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Superiority of HEMOBLAST™ relative to G+T in mean preparation time from the opening of package to product being ready to use</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Non-inferiority of HEMOBLAST™ relative to G+T for success at achieving hemostasis within 3 minutes</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Superiority of HEMOBLAST™ relative to G+T for success at achieving hemostasis within 6 minutes</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Superiority of HEMOBLAST™ relative to G+T for success at achieving hemostasis within 3 minutes</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">412</enrollment>
  <condition>Hemostasis</condition>
  <arm_group>
    <arm_group_label>Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HEMOBLAST Bellows</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Absorbable gelatin sponge, USP with thrombin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HEMOBLAST Bellows</intervention_name>
    <arm_group_label>Investigational</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Absorbable gelatin sponge, USP with thrombin</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Subject is undergoing an elective open cardiothoracic, abdominal, or orthopedic
             lower extremity surgery;

               -  Subject or an authorized legal representative is willing and able to give prior
                  written informed consent for investigation participation;

               -  Subject undergoing cardiothoracic surgery is not allergic to protamine; and

               -  Subject is 21 years of age or older.

        Exclusion Criteria:

          -  • Subject is undergoing a laparoscopic, thoracoscopic, or robotic surgical procedure;

               -  Subject is undergoing a neurologic surgical procedure;

               -  Subject is undergoing a spinal surgical procedure;

               -  Subject is undergoing an emergency surgical procedure;

               -  Subject is pregnant, planning on becoming pregnant during the follow-up period,
                  or actively breast-feeding;

               -  Subject has a clinically significant coagulation disorder or disease, defined as
                  a platelet count &lt; 100,000 per microliter or International Normalized Ratio &gt; 1.5
                  within 4 weeks of surgery;

               -  Subject receiving intravenous heparin within 12 hours before surgery or oral
                  Coumadin within 2 days before surgery;

               -  Subject receiving antiplatelet medications within 5 days prior to surgery;

               -  Subject undergoing abdominal or orthopedic lower extremity surgery receiving
                  aspirin within 7 days prior to surgery;

               -  Subject has an active or suspected infection at the surgical site;

               -  Subject has had or has planned to receive any organ transplantation;

               -  Subject has a known sensitivity or allergy to bovine and/or porcine substance(s)
                  or any other component(s) of the hemostatic agent;

               -  Subject has ASA classification of 5;

               -  Subject has a life expectancy of less than 3 months;

               -  Subject has a known psychiatric disorder, which in the opinion of the Principal
                  Investigator, would preclude the subject from completing this clinical study;

               -  Subject has a documented severe congenital or acquired immunodeficiency;

               -  Subject has religious or other objections to porcine, bovine, or human
                  components;

               -  Subject in whom the investigational or control device will be used at the site of
                  a valve replacement or repair;

               -  Subject in whom the investigational or control device will be used at the site of
                  a synthetic graft or patch implant;

               -  Subject is currently participating or has participated in another clinical trial
                  within the past 30 days and is receiving/has received an investigational drug,
                  device, or biologic agent; and

               -  Subject is not appropriate for inclusion in the clinical trial, per the medical
                  opinion of the Principal Investigator.

        Intraoperative Eligibility Criteria:

          -  Subject does not have an active or suspected infection at the surgical site;

          -  Subject undergoing cardiothoracic surgery with anticoagulation must have
             anticoagulation reversed prior to target bleeding site (TBS) identification and
             treatment;

          -  Subject in whom the Investigator is able to identify a TBS for which any applicable
             conventional means for hemostasis are ineffective or impractical; and

          -  Subject has a TBS with an SBSS score of 1, 2, or 3.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Chapman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CORE Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lotus Clinical Research</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Plastic Surgery</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Hospital - Johns Hopkins Medicine</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Hanover</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center / New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunstad Kortesis Center</name>
      <address>
        <city>Huntsvill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Liver Disease and Transplant Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Medical</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2016</study_first_submitted>
  <study_first_submitted_qc>May 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2016</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
    <mesh_term>Gelatin Sponge, Absorbable</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

